- Home
- XGN vs NRXP Comparison
XGN vs NRXP Comparison
Compare XGN & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XGN | NRXP |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 54.2M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | XGN | NRXP |
|---|---|---|
| Price | $2.70 | $2.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $8.86 | ★ $38.00 |
| AVG Volume (30 Days) | 177.8K | ★ 1.0M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.12 | $2,547.84 |
| Revenue Next Year | $13.00 | $1,591.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $1.65 |
| 52 Week High | $12.23 | $3.84 |
Technical Indicators
Market Signals| Indicator | XGN | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 66.41 |
| Support Level | $2.59 | $2.85 |
| Resistance Level | $3.29 | $3.28 |
| Average True Range (ATR) | 0.17 | 0.21 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 12.05 | 69.92 |
Price Performance
Historical ComparisonAbout XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.